Weight-loss drug shortages prompt copycats and counterfeits

Soaring demand for new hormone-mimicking diabetes and anti-obesity drugs, coupled with difficulties in scaling up supplies, have led to severe shortages. Both Novo Nordisk and Eli Lilly have taken legal action to try and limit efforts of compounding pharmacies and wellness spas making copycat versions of their drugs in the US, while outright counterfeits are surfacing in several markets.